Inflammatory cytokine and chemokine profiles are associated with patient outcome and the hyperadrenergic state following acute brain injury by Alex P. Di Battista et al.
RESEARCH Open Access
Inflammatory cytokine and chemokine
profiles are associated with patient
outcome and the hyperadrenergic state
following acute brain injury
Alex P. Di Battista1,2* , Shawn G. Rhind1,3, Michael G. Hutchison3,4, Syed Hassan1,2, Maria Y. Shiu1,3, Kenji Inaba5,6,
Jane Topolovec-Vranic4, Antonio Capone Neto10, Sandro B. Rizoli4,7,8,9 and Andrew J. Baker2,4,7,8,9
Abstract
Background: Traumatic brain injury (TBI) elicits intense sympathetic nervous system (SNS) activation with profuse
catecholamine secretion. The resultant hyperadrenergic state is linked to immunomodulation both within the brain
and systemically. Dysregulated inflammation post-TBI exacerbates secondary brain injury and contributes to unfavorable
patient outcomes including death. The aim of this study was to characterize the early dynamic profile of circulating
inflammatory cytokines/chemokines in patients admitted for moderate-to-severe TBI, to examine interrelationships
between these mediators and catecholamines, as well as clinical indices of injury severity and neurological outcome.
Methods: Blood was sampled from 166 isolated TBI patients (aged 45 ± 20.3 years; 74.7 % male) on admission, 6-, 12-,
and 24-h post-injury and from healthy controls (N = 21). Plasma cytokine [interleukin (IL)-1β, -2, -4, -5, -10, -12p70, -13,
tumor necrosis factor (TNF)-α, interferon (IFN)-γ] and chemokine [IL-8, eotaxin, eotaxin-3, IFN-γ-induced protein (IP)-10,
monocyte chemoattractant protein (MCP)-1, -4, macrophage-derived chemokine (MDC), macrophage inflammatory
protein (MIP)-1β, thymus activation regulated chemokine (TARC)] concentrations were analyzed using high-sensitivity
electrochemiluminescence multiplex immunoassays. Plasma catecholamines [epinephrine (Epi), norepinephrine (NE)]
were measured by immunoassay. Neurological outcome at 6 months was assessed using the extended Glasgow
outcome scale (GOSE) dichotomized as good (>4) or poor (≤4) outcomes.
Results: Patients showed altered levels of IL-10 and all chemokines assayed relative to controls. Significant differences in
a number of markers were evident between moderate and severe TBI cohorts. Elevated IL-8, IL-10, and TNF-α, as well as
alterations in 8 of 9 chemokines, were associated with poor outcome at 6 months. Notably, a positive association was
found between Epi and IL-1β, IL-10, Eotaxin, IL-8, and MCP-1. NE was positively associated with IL-1β, IL-10, TNF-α,
eotaxin, IL-8, IP-10, and MCP-1.
Conclusions: Our results provide further evidence that exaggerated SNS activation acutely after isolated TBI in
humans may contribute to harmful peripheral inflammatory cytokine/chemokine dysregulation. These findings
are consistent with a potentially beneficial role for therapies aimed at modulating the inflammatory response
and hyperadrenergic state acutely post-injury.
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Background
Growing experimental and clinical evidence indicates that
inflammation is an integral component to the pathogenesis
of secondary injury after traumatic brain injury (TBI) [1, 2].
Its effects are not limited to the brain parenchyma, as sys-
temic inflammation is a noted consequence of TBI, and can
impact patient outcome by exacerbating cerebral tissue in-
jury and contributing to systemic complications such as
nosocomial infection and multiple organ failure [2–4].
While potentially harmful, bi-directional neuroimmune
communication between the central nervous system (CNS)
and the periphery is essential for neuronal repair and regen-
eration [5]. The duality of this process is highlighted by a
number of failed clinical trials aimed broadly at reducing or
inhibiting inflammation [6]. Hence, a better understanding
of the underlying mechanisms governing the inflammatory
response to isolated TBI in humans can help guide future
therapeutic strategies and improve patient outcome.
In an effort to restore vital homeostasis in the face of
TBI, activation of the sympathetic nervous system
(SNS) results in a massive secretion of catecholamines
[epinephrine (Epi), norepinephrine (NE)] into the per-
iphery as part of the generalized host stress response to
trauma [7–13]. Moreover, we have recently demon-
strated in a large group of moderate-to-severe TBI
patients, that both NE and Epi are elevated in a dose-
dependent fashion according to injury severity, and that
prolonged elevation of NE and Epi throughout the first
24 h after hospital admission is highly correlated with
adverse patient outcomes [14].
It has been hypothesized that early SNS activation after
TBI may influence the inflammatory response both locally
and systemically. This occurs prototypically as a response
to elevations in cerebral IL-1β concentrations and subse-
quent initiation of both the local and systemic acute phase
response [4, 15–18]. In addition, trauma-induced activa-
tion of NE terminals in peripheral organs such as the liver
and spleen may lead to the systemic release of inflamma-
tory mediators into the circulation [4, 19, 20]. It is also
possible that elevated concentrations of peripheral cate-
cholamines can differentially alter cytokine/chemokine
production in circulating lymphocytes [21]. NE and Epi
interact with α- and β-adrenergic receptors expressed
on leukocytes and other tissues, influencing the
production of inflammatory mediators from these cells
[22–25]. Furthermore, β-blocker therapy in human TBI
has been associated with improved outcome [26, 27], and
a number of animal studies using pharmacological
blockade of β-adrenergic receptors have shown
concomitant attenuation of the inflammatory response
and improved outcome after treatment [28–30]. How-
ever, no previous clinical studies have evaluated the
relationship between the SNS and systemic inflammation
in isolated TBI patients.
Elevations in a number of cytokines, including inter-
leukin (IL)-1β, -6, -10, and TNF-α, have been identified
in the circulation of TBI patients within hours of injury
[31–36]. However, their relationship to patient survival
and outcome is less clear, likely owing to the heteroge-
neous nature of both primary brain injury (i.e., focal vs.
blunt trauma and extracranial complications) and the
complexity of secondary injury processes. Additionally,
correlations have been found between early elevations in
peripheral cytokines and poor patient outcome [37–40],
although others have found no association [34, 41] or
have even identified inverse relationships between cytokines
and risk of infection after injury [42]. Moreover, chemo-
kines appear to play an important role in TBI pathophysi-
ology [43], though human studies to date have focused
predominantly on IL-8 and MCP-1 [39, 44, 45] and require
further characterization.
Therefore, the purpose of this study was to (1) identify
the temporal profile of a panel of circulating cytokines
and chemokines acutely after injury in both moderate and
severe isolated blunt TBI patients; (2) identify possible in-
terrelationships between circulating catecholamines and
cytokines/chemokines post-injury; (3) to evaluate these
markers in patients stratified according to 6-month neuro-
logical outcome and mortality.
Methods
Ethics statement
The study protocol complied with the ethical guidelines
of the Declaration of Helsinki of 1975 and was approved
by the Research Ethics Boards and Institutional Review
Boards of the participating hospitals. All patients’ fam-
ilies received a comprehensive description of the study
and gave written informed consent for their relatives’ par-
ticipation. In the absence of a substitute decision-maker,
consent was delayed in accordance with the Tri-Council
Policy Agreement for Research in Emergency Health Situ-
ations (Article 2.8); delayed written consent for partici-
pation in the study was subsequently obtained from
next-of-kin or, where possible, directly from the patient
once they had recovered sufficiently. Informed consent for
a single blood sample was also obtained from healthy (con-
trol) volunteers.
Patients and controls
Potential study participants were admitted to Sunny-
brook Health Sciences Centre (Toronto, ON, Canada),
St. Michael’s Hospital (Toronto, ON, Canada), and Los
Angeles County + University of Southern California
(USC) Medical Center (Los Angeles, CA). Upon admis-
sion, patients with an isolated TBI, defined by a Glasgow
coma scale (GCS) score of <13 and a non-head abbrevi-
ated injury score (AIS) of ≤2, were considered for inclu-
sion. Patients with an elapsed time between trauma and
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hospital admission of >3 h, with a penetrating brain in-
jury, <16 years of age, pregnant, taking β-blockers, lack-
ing vital signs prior to admission, or clinically brain dead
on admission were excluded. A healthy control group
with no history of brain injury was included for a single
blood donation for analysis of the selected panel of sol-
uble inflammatory markers.
Study design and procedures
Upon hospital admission, clinical and demographic data
were obtained from eligible patients: demographics—age
and sex ; clinical information—mechanism of injury, elapsed
time from the trauma to the emergency room, injury sever-
ity score (ISS), and AIS head; neurological status—level of
consciousness categorized by the GCS, pupil size and re-
activity, seizures, and alcohol level; clinical status—blood
pressure, tracheal intubation, spontaneous vs. mechanical
ventilation, oxygen saturation, and temperature; and med-
ical history—past medical history, present medications in-
cluding β-blockers and anticoagulants. Routine laboratory
exams and imaging were also completed upon admission,
including chest radiography and computerized tomography
(CT) scans. All significant clinical events during the first
24 h were recorded, including, but not limited to, sepsis/in-
fection, organ failure, any medical treatments administered,
surgical procedures, and any other significant changes in
clinical parameters. Organ failure was defined by the fol-
lowing criteria: (1) arterial hypoxemia—PaO2/FiO2 < 300;
(2) acute oliguria—urine output <0.5 mL/kg/h for at least
2 h despite adequate fluid resuscitation; (3) creatine in-
crease—>0.5 mg/dL or 44.2 μmol/L; (4) coagulation
abnormalities—INR > 1.5 or aPTT > 60 s; (5) ileus—ab-
sent bowel sounds; (6) thrombocytopenia—platelet count
<100,000 μ/L; and (7) hyperbilirubinemia—plasma total
bilirubin >4 mg/dL or 70 μmol/L.
For patients who died, the cause of death was recorded
and classified as TBI-related or non-TBI related. Upon
hospital discharge, at 28 days and at 6-months, patient
outcome was assessed using the extended Glasgow out-
come scale (GOSE) .
Blood sample collection
Venous blood samples were drawn as soon as possible
after admission to the trauma room or emergency depart-
ment, and again at 6-, 12-, and 24-h post-injury. Samples
were drawn into either 10 mL K2EDTA [with 4 mM
sodium metabisulfite (Na2S2O5)] or 10-mL sodium hep-
arin vacutainers (Vacutainer, Becton Dickinson, Ruther-
ford, NJ). Specimens were immediately centrifuged at
1600×g for 15 min at 4 °C; the plasma supernatant was
then separated into six (1–2 mL) aliquots and frozen at
−70 °C until subsequent analysis.
Multiplex cytokine and chemokine measurements
Immunoreactive plasma levels of selected cytokines and
chemokines were analyzed with Meso Scale Discovery
(MSD) 96-Well MULTI-SPOT® Ultra-Sensitive Human
Immunoassay Kits, using electrochemiluminescence de-
tection on an MSD Sector Imager™ 6000 with Discovery
Workbench software (version 3.0.18) (MSD®, Gaitherburg,
MD, USA). Cytokines were measured using the TH1/TH2
10-plex kit, which included nine markers (excluding IL-8):
IFN-γ, IL-1 β, -2, -4, -5, -10, -12p70, -13, and TNF-α.
Chemokines were measured using the Chemokine 9-plex,
which also included nine markers: eotaxin, eotaxin-3,
MIP-1β, thymus activation regulated chemokine (TARC),
IP-10, IL-8, MCP-1, MDC, and MCP-4 (Additional file 1:
Table S1). All assays were performed according to manu-
facturer’s instructions, in duplicates, and without alter-
ations to the recommended standard curve dilutions.
Briefly, samples were thawed on ice and added to a 96-
well MULTI-SPOT® plate coated with capture antibodies
in a spatially distinct fashion. SULFO-TAG® labeled detec-
tion antibodies were then added to each of the wells to
complete the sandwich format, and a read buffer was
added to alter the chemical environment for electrochemi-
luminescence. The subsequent reaction resulted in the
emission of light from the labeled analytes, which was
then quantified to approximate the concentration (pg/mL)
of each protein present in the sample.
Catecholamine measurements
Plasma Epi and NE levels were determined from dupli-
cate samples using a competitive enzyme immunoassay
method according to the manufacturer’s instructions
(Bi-CAT EIA, ALPCO Diagnostics, Salem, NH). Briefly,
plasma Epi and NE were extracted using a cis-diol-
specific affinity gel, acylated and then derivatized enzymati-
cally into N-acylmetanephrine and N-acylnormetanephrine,
respectively. Antibody bound to the solid-phase catechol-
amines were detected by an anti-rabbit IgG-peroxidase
conjugate using tetramethylbenzidine as a substrate. Quan-
tification of unknown samples was achieved by comparing
their absorbance with a reference curve prepared with
known standard concentrations included in the kit.
Statistical analysis
Demographic and clinical parameters are expressed as the
mean ± standard deviation (SD) unless otherwise stated,
while blood marker concentrations are graphically dis-
played as the median and interquartile range. Comparison
of inflammatory marker levels between TBI patients at
each sampled time point and healthy control subjects was
performed using a Kruskal-Wallis analysis of variance,
with Dunn’s multiple comparisons post hoc test. To assess
6-month neurological outcome, patients were dichoto-
mized into favorable (GOSE 5–8) and unfavorable (GOSE
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1–4) outcomes. Mortality was assessed by stratifying pa-
tients into two groups, “survivors” and “non-survivors.”
Death was further stratified as either “neurologic” or
“non-neurologic.” Differences in cytokine and chemokine
concentrations between moderate and severe TBI patients,
unfavorable and favorable outcome, survivors and non-
survivors, and neurologic and non-neurologic death were
assessed by Mann-Whitney U. To identify possible corre-
lations between catecholamines and inflammatory marker
concentrations, pooled data over all time points was eval-
uated by Spearman’s ρ. To generate an aggregate inflam-
mation score (IS), peak quartile rank scores from each
marker associated with both unfavorable outcome and
survival were summed [36, 46]. For each marker, values
>75th percentile were given a score of 4, values between
the 50th and 75th percentile were given a score of 3,
values between the 25th and 50th percentile were given a
score of 2, and values <25th percentile were given a score
of 1. When lower concentrations of a marker were associ-
ated with unfavorable patient outcome, the scoring system
was reversed, hence values <25th percentile were given a
score of 4, while values >75th percentile were given a
score of 1. Quartile scores of each marker were added,
resulting in an aggregate score; six markers were included,
allowing for a score ranging from 6 to 24. Patients were
then dichotomized into high- vs. low-inflammation cat-
egories based on the median aggregate IS [47]. In addition,
to assess the ability of cytokines and chemokines to pre-
dict poor patient outcome and death while controlling for
injury severity, a multivariate binomial logistic regression
analysis was employed. All markers were quartiled in
order to standardize unit increases for statistical compari-
son. Each individual marker was added independently to a
model containing GCS and AIS head scores. The binary
dependent outcome variables were 6-month GOSE or sur-
vival. Biomarker data was not statistically analyzed or
graphically displayed unless at least 50 % of the samples
analyzed were within the detection range of the assay, or
contained replicate values with a coefficient of variation
(CV) <25 %. Statistical significance in all analyses was in-
dicated by a p value of ≤0.05. All data were analyzed using
GraphPad Prism Version 6.0d (GraphPad Inc, CA, USA)
and Stata Version 13.1 (StataCorp, TX, USA).
Results
Demographics and clinical characteristics
Table 1 summarizes the demographic, clinical, and out-
come data for the 166 (33 moderate, 133 severe) patients
analyzed in the study. Subjects were predominantly male
(n = 124, 74.7 %), with an average age of 45.8 ± 20.3 years
. The majority of patients had an unfavorable outcome
at 6 months, classified as a GOSE score of 1–4 (n = 102,
61.4 %). Eighteen patients (10.8 %) developed organ fail-
ure, and there were 45 (27.1 %) deaths. Among the 21
healthy control subjects, 71.4 % were males (n = 15), and
the mean age was 32.7 ± 7.8 years (data not shown).
Plasma concentrations of inflammatory markers in
moderate and severe TBI patients
Plasma concentrations of cytokines and chemokines
stratified according to moderate (GCS 9–12) and severe
(GCS 3–8) TBI are shown in Fig. 1. IL-10 was the only
cytokine altered in patients compared with healthy con-
trols—median admission IL-10 levels were 5 - and 9 - fold
higher, respectively, in moderate and severe TBI patients,
and were significantly elevated at all time points (Fig. 1a).
Furthermore, at 6, 12, and 24 h after hospital admission,
mean IL-10 levels in severe TBI patients were significantly
elevated (~2-fold at admission, 6, and 24 h) compared to
moderate TBI patients (Fig. 1a).
Significant alterations in all nine chemokines were de-
tected in TBI patients dichotomized by injury severity vs.
healthy controls (Fig. 1c–k). The most dramatic increase
Table 1 Demographic and clinical characteristics for TBI patients







Age (years) 45.8 ± 20.3 49.5 ± 19.7 44.9 ± 20.4
Male —n (%) 124 (74.7) 23 (69.7) 101 (75.9)
Clinical characteristics
Time to ED (min) 77.6 ± 63.5 74.7 ± 64.8 78.3 ± 63.4
ISS score 24.4 ± 11.8 18.8 ± 11.5 25.9 ±
11.5
AIS head 4.1 ± 1.1 3.5 ± 1.2 4.3 ± 1.0
GCS 5.9 ± 3.0 10.5 ± 1.3 4.7 ± 1.9
Marshall score—n (%)
I 28 (16.9) 11 (33.3) 17 (12.8)
II 76 (45.8) 16 (48.5) 60 (45.1)
III 13 (7.8) 1 (3.0) 12 (9.0)
IV 27 (16.3) 3 (9.1) 24 (18.0)
Evacuated mass lesion 21 (12.6) 2 (6.1) 19 (14.3)
Non-evacuated mass lesion 1 (0.6) 0 (0.0) 1 (0.7)
Pre-injury comorbidities—n
(%)
45 (27.1) 14 (42.4) 31 (23.3)
Outcomes
Mortality—n (%) 45 (27.1) 1 (3.0) 44 (33.0)
Neurosurgery
performed—n (%)
47 (28.3) 5 (15.1) 42 (31.6)
Sepsis/infection—n (%) 42 (25.3) 7 (21.2) 35 (26.3)
Organ failure—n (%) 18 (10.8) 0 (0.0) 18 (13.5)
6-month GOSE 4.0 ± 2.5 5.7 ± 2.1 3.6 ± 2.5
Unless otherwise stated, results are expressed as mean ± standard deviation (SD)
Abbreviations: TBI traumatic brain injury, ED emergency department, ISS injury
severity score, AIS abbreviated injury scale, GCS Glasgow coma scale, GOSE
extended Glasgow outcome scale
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was seen in IL-8: patient concentrations peaked at 6 h
after hospital admission and were nearly 3.5-fold higher in
those with severe TBI vs. healthy control subjects (median
concentrations, 12.2 vs. 3.5 pg/mL, respectively) (Fig. 1f).
In addition, at admission and 6 h, mean IL-8 levels were
higher in patients with severe TBI compared to those with
moderate TBI (Fig. 1f). Significant increases in MCP-1
concentrations in severe vs. moderate TBI patients were
also identified (6 h) (Fig. 1g). Conversely, IP-10 and MDC
concentrations were decreased in both moderate and se-
vere TBI patients compared with controls (Fig. 1e, i, re-
spectively), while eotaxin was decreased in severe TBI
patients only (Fig. 1c). MCP-4 levels were elevated on ad-
mission in moderate TBI patients compared with healthy
Fig. 1 Plasma cytokine and chemokine concentrations in moderate and severe TBI patients sampled over 24 h. Cytokines interleukin (IL)-10 (a),
tumor necrosis factor (TNF)-α (b). Chemokines eotaxin, eotaxin-3, interferon-gamma induced protein (IP)-10, IL-8, monocyte chemoattractant protein
(MCP)-1, -4, macrophage-derived chemokine (MDC), macrophage inflammatory protein (MIP)-1β, and thymus and activation regulated chemokine
(TARC) (c–k) in moderate (GCS 9–12, n = 33, open squares) and severe (GCS 3–8, n = 133, closed squares) TBI patients within the first 24 h of hospital
admission vs. healthy control subjects (no TBI, n = 21, open circles). Lines represent the median and interquartile range. *p < 0.05 vs. healthy controls by
Kruskal-Wallis. †p < 0.05 vs. moderate TBI by Mann-Whitney U test
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subjects, but were lower in severe TBI patients compared
with healthy subjects at 12 and 24 h (Fig. 1h). Further-
more, MCP-4 levels were lower in severe TBI patients at
all sampled time points compared to moderate TBI pa-
tients (Fig. 1h). Eotaxin levels were elevated in severe TBI
patients at admission, but similar to MCP-4, were de-
creased at 12 and 24 h (Fig. 1c).
Correlation between SNS and inflammatory markers
Pooled concentrations of NE and Epi were associated with
a number of inflammatory markers acutely after TBI
(Table 2). IL-1β and IL-10 were positively correlated to Epi,
with IL-10 displaying the strongest correlation (r = 0.44,
P < 0.01) (Table 3). NE concentrations were positively
related to IL-1β, IL-10, and TNF-α (Table 2). Similar to
Epi, NE was most strongly correlated to IL-10 (r = 0.45,
P < 0.01). In addition, IL-1β displayed a stronger posi-
tive association with NE (r = 0.28, P < 0.01) than with
Epi (r = 0.11, P < 0.03) (Table 2).
E otaxin, IL-8, and MCP-1 were positively related to
both NE and Epi, while IP-10 was associated with NE
only (Table 2). The strongest relationship between cate-
cholamines and chemokines was found between IL-8 and
NE (r = 0.39, P < 0.01); IL-8 also displayed the highest cor-
relation of any chemokine with Epi (r = 0.35, P < 0.01)
(Table 2).
Six-month neurological outcome
Within 24 h of hospital admission, significant differences
in plasma levels of three cytokines and three chemokines
were observed between patients with favorable and un-
favorable 6-month neurological outcome (Fig. 2a–f re-
spectively). IL-10 displayed the most profound difference
of all cytokines assessed: concentrations at 6 h were near
3-fold higher in patients with unfavorable vs. favorable
6-month outcome (median concentrations, 13.3 vs.
4.5 pg/mL, respectively) and were significantly elevated
at all sampled time points (Fig. 2b). In addition, both IL-
1β and TNF-α concentrations were elevated at 6 and
12 h in patients with unfavorable vs. favorable outcome
(Fig. 2a, c, respectively). IL-8 levels were significantly
elevated at all sampled time points, with a peak differ-
ence at 6 h (13.6 vs. 8.7 pg/mL in unfavorable vs. favor-
able outcome, respectively), while MCP-1 concentrations
were significantly elevated at admission and 24 h in pa-
tients with unfavorable vs. favorable outcome (Fig. 2d, e,
respectively).
Mortality
Alterations in inflammatory marker concentrations were
observed in patients who lived vs. those who died; differ-
ences were noted in three cytokines and eight chemo-
kines (Fig. 3a–k, respectively). IL-10 levels were elevated
at 6, 12, and 24 h after admission in patients who died
compared to those who lived. In non-survivors, IL-1β
concentrations were 2- fold higher at 12 h (median con-
centrations, 0.9 vs. 0.4 pg/mL, respectively), and IL-10
concentrations were 4- fold higher at 6 h (median con-
centrations, 28.1 vs. 6.5 pg/mL, respectively) (Fig. 3a, b,
respectively). Similar to the 6-month neurological out-
come, IL-8 levels displayed the greatest elevation of all
chemokines assessed in patients who died vs. those
who lived (Fig. 3d). IL-8 concentrations were signifi-
cantly elevated at all sampled time points, with the
greatest disparity at 6 h, where patients who died had
concentrations >2-fold higher than those who lived
(median concentrations, 23.9 vs. 9.3 pg/mL, respect-
ively) (Fig. 3d). Conversely, MCP-4, MDC, and TARC
concentrations at 24 h after hospital admission were
significantly lower in TBI patients who died compared
to survivors (Fig. 3g, h, j, respectively).
Secondary complications controlled for injury severity
Six-month GOSE
When controlled for admission GCS and AIS head
scores, and standardized according to ranked quartiles,
IL-1β (peak, 6 h; OR (odds ratio) 1.84; 95 % confidence
interval (CI) 0.90–2.25), IL-10 (peak, 6 h; OR 1.76; 95 %
CI 1.25–2.70), and TNF-α (peak, 6 h; OR 1.61; 95 % CI
Table 2 Catecholamine and inflammatory marker correlations
Marker Catecholamines
Epinephrine Norepinephrine
r P value r P value
Cytokines (pg/mL)
IL-1β 0.11 0.04* 0.28 <0.01*
IL-5 −0.07 0.19 0.01 0.90
IL-10 0.44 <0.01* 0.45 <0.01*
TNF-α 0.00 0.93 0.14 <0.01*
Chemokines (pg/mL)
Eotaxin 0.16 <0.01* 0.16 0.01*
Eotaxin-3 0.08 0.15 0.05 0.31
IL-8 0.35 <0.01* 0.39 <0.01*
IP-10 −0.00 0.88 0.10 0.02*
MCP-1 0.23 <0.01* 0.33 <0.01*
MCP-4 0.06 0.17 0.05 0.24
MDC −0.00 0.98 −0.09 0.04*
MIP-1β −0.00 0.97 0.16 <0.01
TARC −0.05 0.24 0.03 0.43
Abbreviations: IL interleukin, TNF-α tumor necrosis factor-alpha, IP-10
interferon-gamma induced protein-10, MCP monocyte chemoattractant pro-
tein, MDC macrophage-derived chemokine, MIP-1β macrophage inflammatory
protein–1β, TARC thymus and activation regulated chemokine
*p < 0.05 via Spearman’s ρ
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1.13–2.29) were significant independent predictors of un-
favorable 6-month outcome (GOSE 1–4) (Table 3). In
addition, IL-8 (peak, admission; OR 1.66; 95 % CI 1.15–
2.39) and MDC (peak, 12 h; OR 1.45; 95 % CI 1.02–2.05)
were independent predictors of unfavorable outcome
(Table 3).
Mortality
Controlled for admission GCS and AIS head scores, pa-
tient death was independently associated with three cy-
tokines and four chemokines (Table 3). IL-10 was the
greatest predictor of death of all cytokines analyzed
(peak, 6 h; OR 2.82; 95 % CI 1.63–4.87). However, the
strongest predictor of death among chemokines as well
as all evaluated inflammatory markers was IP-10 (peak,
admission; OR 3.11; 95 % CI 1.83–5.27) (Table 3).
Neurologic vs non-neurologic death
Differences in specific inflammatory biomarkers were
observed between patients who lived vs. those who died
by neurologic or non-neurologic organ failure. IL-1β was
significantly elevated in patients who died by neurologic
death vs. those who survived at 6, 12, and 24 h; no dif-
ference was found between those who died by organ fail-
ure and those who survived (Fig. 4a). IL-10 levels were
elevated in patients succumbing to both neurologic and
non-neurologic death compared to those who survived
at all time points except admission (Fig. 4b). Similarly,
IL-8 concentrations were elevated in neurologic and
non-neurologic death compared to patients who died at
6 h, but were elevated only in patients succumbing to
neurologic death at all other sampled time points
(Fig. 4c). MCP-1 concentrations were elevated in neuro-
logic death vs. survival at admission, 6, and 12 h, but
were lower at 24 h in patients who died by non-
neurologic organ failure vs. neurologic death (Fig. 4f ). In
addition, MIP-1β concentrations were significantly lower
in patients who died by non-neurologic organ failure vs.
neurologic death at 6 and 24 h (Fig. 4g).
Combined inflammatory score and patient characteristics
A combined IS was created in a subset of 76 patients
using three cytokines (IL-1β, -10, and TNF-α) and three
chemokines (IL-8, MCP-1, MDC) that were associated
with both unfavorable patient outcome at 6 months and
mortality. Compared to patients with low a IS (<15), pa-
tients with a high IS (≥15) had significantly greater mean
NE levels over 24 h from hospital admission, while Epi
levels did not statistically differ (Table 4). Greater injury
severity, as assessed by admission GCS, AIS head, and
ISS scores, was associated with a high IS. In addition,
patients with poor outcomes (unfavorable 6-month
GOSE and death) had high IS scores (Table 4).
Discussion
In this study we demonstrated that following isolated TBI,
acute alterations in systemic cytokine and chemokine
levels were associated with unfavorable patient outcome
and death. Our sample size of 166 patients is, to our
knowledge, the largest study to date to characterize the
systemic inflammatory response in isolated TBI. A com-
pelling finding of this work was the identification of a rela-
tionship between SNS activity and systemic inflammation
acutely post-injury. In addition, our findings addressed the
heterogeneous and complex nature of TBI which has con-
founded our understanding of the pathophysiology and
clinical relevance of post-traumatic systemic inflammation
[1]. Specifically, our study population consisted of isolated
TBI patients with non-penetrating injuries, stratified ac-
cording to injury severity, and sampled acutely at four
Table 3 Binomial logistic regression models assessing the ability
of inflammatory markers to predict poor patient outcome,
controlling for injury severity
Marker Admission Hours after admission
6 12 24
OR P value OR P value OR P value OR P value
Unfavorable 6-month GOSE
IL-1β 0.84 0.489 1.84* 0.002 1.65* 0.009 0.91 0.673
IL-10 1.18 0.376 1.76* 0.005 1.57* 0.019 1.48* 0.034
TNF-α 1.49* 0.024 1.61* 0.008 1.50* 0.021 1.30 0.138
IL-8 1.66* 0.007 1.48* 0.030 1.44* 0.036 1.33 0.104
MCP-1 1.42 0.052 1.09 0.603 1.24 0.213 1.39 0.067
MDC 1.10 0.586 0.90 0.515 1.45 0.037* 0.85 0.363
Mortality
IL-1β 1.02 0.935 1.06 0.825 1.85* 0.038 1.15 0.598
IL-10 1.19 0.417 2.82* <0.001 2.09* 0.003 2.20* 0.003*
TNF-α 1.58* 0.027 1.77* 0.007 1.58* 0.033 1.19 0.395
IL-8 1.31 0.168 1.89* 0.005 1.84 0.010* 1.37 0.176
IP-10 3.11* <0.001 2.06* 0.002 1.59* 0.030 1.19 0.400
MCP-1 1.26 0.230 1.46 0.069 1.57* 0.035 0.91 0.674
MCP-4 1.43 0.090 1.49 0.065 0.99 0.964 0.57* 0.023
MDC 1.03 0.864 0.91 0.620 1.14 0.529 0.71 0.114
MIP-1β 1.13 0.544 1.27 0.243 1.29 0.221 0.89 0.592
TARC 0.95 0.801 1.00 0.991 0.77 0.231 0.56* 0.015
Eotaxin 1.90* 0.005 1.90* 0.007 1.33 0.208 0.79 0.304
Models were controlled for admission GCS and AIS head scores
All blood biomarker concentrations were standardized by quartiles. A one-unit
increase is equivalent to a 25 % increase in biomarker concentration
Abbreviations: OR odds ratio, GOSE extended Glasgow outcome scale, IL
interleukin, TNF-α tumor necrosis factor-alpha, MCP monocyte chemoattractant
protein, MDC macrophage-derived chemokine, IP-10 interferon-gamma induced
protein-10, MIP-1β macrophage inflammatory protein–1β, TARC thymus and
activation regulated chemokine
*p < 0.05
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time points over the first 24 h from hospital admission
(Additional file 2: Table S2).
We found IL-10 was the most prominently altered of all
cytokines acutely after injury, and was positively correlated
with injury severity. While this is in general agreement with
previous findings [21, 37, 48, 49], few studies have assessed
IL-10 in isolated TBI patients [21, 49]. Furthermore, we
are aware of only one previous report that evaluated IL-10
in isolated TBI patients dichotomized by injury severity,
albeit in a population of 26 patients that assessed injury
severity at 7 days post-injury [50]. Also, in agreement with
previous research, unfavorable patient outcome and mor-
tality were associated with elevated peripheral concentra-
tions of IL-1β, IL-10, and TNF-α [32, 37, 46, 48].
Importantly, the relationships between cytokines and pa-
tient outcome were significant even after controlling for
injury severity, suggesting a possible independent role of
these mediators in secondary injury pathogenesis. More-
over, our results provide evidence that certain cytokines
may be associated with specific outcomes. For example,
IL-1β and TNF-α were elevated only in patients who died
from neurologic death, while IL-10 was higher in pa-
tients who died as a result of both neurologic and non-
neurologic organ failure. Taken together, these findings
not only reinforce the globally detrimental role of IL-
10 acutely after TBI, but also suggest that peripheral
blood may be a viable source for biomarkers related to
brain injury-specific outcomes.
Systemic concentrations of all nine chemokines ana-
lyzed were significantly different in TBI patients compared
to healthy subjects, and alterations in eight of the nine
chemokines were associated with poor patient outcome.
In addition, we found eotaxin-3, IL-8, MCP-1, and MCP
-4 were associated with injury severity. Similar to our
cytokine analysis, when controlled for injury severity,
seven of the nine chemokines were still related to poor pa-
tient outcome, with increases in admission IP-10 levels
displaying the strongest relationship to death of all inflam-
matory markers analyzed. Notably, while higher IP-10
levels in patients were independently associated with mor-
tality, on average, levels were lower in patients vs. healthy
controls. The reasons for this are unclear, but it is possible
that our total patient values were skewed by lower IP-10
concentrations in survivors vs. those who died. Further-
more, that a number of chemokines were lower in patients
compared to controls, or lower in patients with unfavor-
able vs. favorable outcomes, may speak to the complex
and divergent roles of chemokines in mediating secondary
Fig. 2 Plasma cytokine and chemokine concentrations in TBI patients stratified according to the 6-month GOSE. I nterleukin (IL)-1β, -10, tumor ne-
crosis factor (TNF)-α (a–c). IL-8, monocyte chemoattractant protein (MCP)-1, macrophage-derived chemokine (MDC) (d–f) in TBI patients with un-
favorable (GOSE 1–4, n = 102) vs. favorable (GOSE 5–8, n = 61) 6-month neurological outcome. Lines represent the median and interquartile range.
*p < 0.05 vs. favorable outcome by Mann-Whitney U test
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injury. Our findings are in general agreement with others
who have identified elevations in systemic IL-8 and MCP-
1 after TBI [31, 39, 44, 51, 52] and identified the relation-
ship between this and poor patient outcome [38, 40, 45].
However, to our knowledge, no previous studies have
characterized this diverse array of chemokines in the per-
ipheral blood after human TBI. Interestingly, Helmy et al.
[53] evaluated a number of cytokines and chemokines in
the brain extracellular fluid in 12 TBI patients post-injury.
These authors concluded that among other inflammatory
mediators evaluated, IL-8, MCP-1, IP-10, and MIP-1β
were elevated in the brain extracellular fluid relative to
plasma, and may be centrally produced after TBI. How-
ever, this study did not evaluate plasma levels of these
Fig. 3 Plasma cytokine and chemokine concentrations in TBI patients stratified by mortality. Cytokines interleukin (IL)-1β, -10, tumor necrosis
factor (TNF)-α (a–c). Chemokines IL-8, interferon-gamma producing protein (IP)-10, monocyte chemoattractant protein (MCP)-1, -4, macrophage-
derived chemokine (MDC), macrophage inflammatory protein (MIP)-1β, thymus and activation regulated chemokine (TARC), and eotaxin (d–k) in
TBI patients who died (n = 45) vs. those who lived (n = 119). Lines represent the median and interquartile range. *p < 0.05 vs. lived by
Mann-Whitney U test
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markers in comparison to healthy controls and subse-
quently, the relative systemic changes were not deter-
mined. Furthermore, Chen et al. [54] recently found serum
levels of CXCL12 were significantly related to injury sever-
ity and patient death after isolated human TBI. Collect-
ively, these recent findings and those of the current study
support the deleterious involvement of chemokines beyond
IL-8 and MCP-1 in secondary injury pathophysiology, and
warrants further investigation.
We identified a number of specific correlations be-
tween systemic catecholamines and inflammatory medi-
ators that are consistent with previous experimental
Fig. 4 Plasma cytokine and chemokine concentrations in TBI patients according to the cause of death. I nterleukin (IL)-1β, -10, tumor necrosis
factor (TNF)-α (a–c). IL-8, interferon-gamma producing protein (IP)-10, monocyte chemoattractant protein (MCP)-1, and macrophage inflammatory
protein (MIP)-1β (d–g) in TBI patients who survived (n = 119) vs. those who died by neurologic death (n = 28) or by non-neurologic organ failure
(n = 17). Boxes represent the median and interquartile ranges, and whisker plot lines represent the range. *p < 0.05 vs. patients who survived; †p <
0.05 vs. patients who succumbed to neurologic death, by Kruskal-Wallis
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findings. For example, Woisciechowsky et al. [24] found
that SNS activation after brain trauma results in the sys-
temic release of IL-10. The authors showed that NE and
Epi signaling through peripheral blood monocyte β2-ad-
renergic receptors caused an increase in circulating IL-
10 concentrations, deactivation of circulating monocytes,
and subsequent immunosuppression and infection [24].
That we found a strong association between both NE,
Epi, and IL-10 is consistent with the experimental find-
ings of Woiciechowsky et al. and suggests a mechanistic
role for catecholamines in mediating IL-10 production
in the acute period after isolated TBI. Additionally, it
has been hypothesized that IL-1β may induce SNS acti-
vation after brain trauma [55–57]. Experimental studies
have shown that both CNS and peripherally injected IL-
1β have the ability to stimulate the SNS [55, 58], which
may then mediate leukocyte mobilization and initiate
the hepatic acute phase response [15–18, 55]. This is
consistent with the associations we found between IL-1β
and both NE/Epi . Furthermore, we identified a positive
correlation between NE, Epi, and IL-8 and MCP-1. It
has been suggested that the production and release of
chemokines from the liver, particularly IL-8 and MCP-1,
is an important component of the systemic acute phase
response after TBI [4, 16–18], particularly in mediating
the mobilization and recruitment of leukocytes to the
brain [17, 18, 59, 60]. In a review by Catania and col-
leagues [4], it was hypothesized that systemic chemokine
production and release from the liver post-injury may be
mediated by SNS activation and, specifically, the activa-
tion of sympathetic nerve terminals and subsequent
interaction between tissue macrophages and synaptic NE
[18]. In addition, NE has been found to interact with β-
adrenergic receptors on cultured peripheral blood
mononuclear cells to produce MCP-1 [61], and Epi has
been shown in multiple studies to potentiate LPS-
induced IL-8 production in monocytes [22, 62]. While
the specific mechanism(s) has/have yet to be deter-
mined, the results of the current study are supportive
of catecholamine- mediated chemokine production
after isolated TBI.
While the pathogenesis of systemic inflammation after
TBI remains uncertain, our results provide evidence con-
sistent with a detrimental role for the innate immune sys-
tem in the acute period after injury and further supports
the concept that SNS hyperactivity mediates this process.
Indeed, the application of an inflammation-based prognos-
tic score showed that the net inflammatory effect seen
acutely after TBI is associated with poor patient outcomes,
injury severity, and significant elevations in NE. Further-
more, our findings are generally consistent with the re-
vised interpretation of the systemic inflammatory response
syndrome (SIRS) and compensatory anti-inflammatory
response syndrome (CARS) noted after trauma and sepsis,
which suggests that pro- and anti-inflammatory processes
occur concurrently, not in a phase delayed manner as was
previously hypothesized [63, 64]. We and others have con-
sistently observed that the anti-inflammatory molecule IL-
10 is among the earliest detectable mediators after
trauma [48, 50, 65] and is elevated concurrently with
pro-inflammatory IL-1β, IL-8, TNF-α, and numerous
other chemokines in patients with poor outcomes.
Table 4 Clinical characteristics according to dichotomized inflammatory scores
Characteristics Inflammation—low (IS < 15, n = 33) Inflammation—high (IS ≥ 15, n = 43) P value
Catecholamine levelsa (pmol/L)
Epi 1131.5 (656.0–1901.9) 1655.0 (733.2–4307.4) 0.110
NE 6064.3 (3081.0–18373.4) 12,110.0* (7653.1–37,939.8) 0.013
Injury severity
GCS 7.0 (4.0–9.0) 3.0* (3.0–7.0) 0.002
AIS head 4.0 (3.0–5.0) 5.0* (4.0–5.0) 0.006
ISS 20.5 (16.5–29.5) 29.5* (20.0–35.0) 0.014
Outcome (n)
Sepsis/infection 13 9 0.079
Unfavorable 6-month GOSE 14 33* 0.002
Overall mortality 4 16* 0.014
Neurologic death 2 13* 0.009
Values described as the median and interquartile range unless otherwise stated. IS variables consist of peak differences between unfavorable and favorable
outcome over 24 h in IL-1β (6 h), IL-10 (6 h), TNF-α (6 h), IL-8 (6 h), MCP-1 (admission), and MDC (12 h)
Abbreviations: IS inflammation score, Epi epinephrine, NE norepinephrine, GCS Glasgow coma scale, AIS abbreviated injury scale, ISS injury severity score, GOSE
extended Glasgow outcome scale
*p < 0.05 vs. low inflammatory score by Mann-Whitney U or chi-square, where appropriate
aAverage catecholamine concentrations over 24 h
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Notably, we did not find any association between acute
inflammation and the onset of sepsis/infections. How-
ever, this study did not directly characterize cellular im-
mune function, and previous studies have reported that
immunosuppression and subsequent infection after brain
trauma may be related to impaired cellular immunity, in-
cluding monocyte deactivation [24, 65] and/or suppres-
sion of T cell function [66, 67].
The results of this study should be interpreted in
the context of its limitations. Despite a well-
controlled clinical design and moderately sized cohort
of 166 TBI patients, a larger sample size would have
allowed for further stratification of our patient popu-
lation, particularly regarding variables such as sex, age
and isolated sepsis. Also, we were only able to assess
the level of inflammatory markers in patients’ blood
samples for the first 24 h post-injury, and a longer
sampling period may have been advantageous to
assess the potential for hyperadrenergic mediated im-
munosuppression. In spite of these limitations, this
investigation is one of the most comprehensive in-
flammatory studies in isolated human TBI to date.
The results demonstrated a pronounced systemic
cytokine/chemokine response acutely after isolated
head injury and suggest that this response is associ-
ated with the degree of SNS activation.
Conclusions
A number of peripheral cytokines and chemokines
are altered in the acute period after moderate and se-
vere isolated TBI. These alterations are associated
with unfavorable patient outcomes. Moreover, the sys-
temic inflammatory response after TBI appears to be
mediated, at least in part, by a profound trauma-
induced hyperadrenergic state. In the present study,
we found marked increases in circulating IL-10 and
alterations in all chemokines assessed within 24 h of
hospital admission. Poor patient outcome was associ-
ated with alterations in IL-1β, IL-10, TNF-α, and all
chemokines with the exception of eotaxin-3. Further-
more, circulating NE and Epi levels were positively
correlated with IL-1β, IL-10, IL-8, eotaxin, and MCP-
1. Future controlled clinical studies should continue
to emphasize potential therapeutic interventions that
modulate excessive SNS activation and inflammation,
including treatment with selective adrenergic blocking
agents.
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